Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Puebla City
Clinical trial register · Mexico

Clinical Trials in Puebla City, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1585 matching records held by the registry are in this view. Synced 12 Oct 2026, 03:18 UTC
1585
Studies in scope
all four open statuses
715
Recruiting now
open to new participants
254
Lead sponsors
across recruiting studies
Top sites
Mexico City 591 Monterrey 374 Guadalajara 348 Chihuahua City 175 Mérida 133
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company9 Bristol-Myers Squibb8 Novo Nordisk A/S7 Merck Sharp & Dohme LLC5 Pfizer3
Site location
Mexico City591 Monterrey374 Guadalajara348 Chihuahua City175 Mérida133
All 197 locations
Target enrolment
to

Trials with a site in Puebla City

52 of 1585 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
Novo Nordisk A/S
Phase 3
80
Coyoacán, Monterrey, San Nicolás de los Garza, Cuauhtémoc, Puebla City
2026-08-04
Recruiting
Novo Nordisk A/S
Phase 3
630
Guadalajara, Col Roma Norte, Distrito Federal, San Nicolás de los Garza, Oaxaca City, Puebla City
2026-04-13
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Monterrey, Oaxaca City, Puebla City, Tlalpan
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 3
850
Saltillo, Tijuana, Zapopan, Monterrey, Puebla City, Querétaro
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
750
Guadalajara, Zapopan, Mexico City, Monterrey, Oaxaca City, Puebla City, Querétaro
2026-03-12
Recruiting
Novo Nordisk A/S
Phase 3
460
Monterrey, Puebla City
2026-01-08
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Tijuana, Guadalajara, Zapopan, Mexico City, Monterrey, Oaxaca City, Chihuahua City, Puebla City
2026-01-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Guadalajara, Monterrey, Oaxaca City, Mexico City, Puebla City
2025-11-26
Recruiting
Laboratorios Sophia S.A de C.V.
Phase 3
134
Tijuana, Puebla City
2025-10-27
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Zapopan, Cuauhtémoc, Ciudad de México, Mexico City, Monterrey, Oaxaca City, Mérida, Puebla City, Querétaro
2025-10-23
Recruiting
Eli Lilly and Company
Phase 3
1,630
Chihuahua City, Mexico City, Puebla City, Tijuana
2025-10-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Guadalajara, Benito Juárez, Monterrey, Oaxaca City, Chihuahua City, Mexico City, Puebla City
2025-10-08
Recruiting
Pfizer
Phase 3
680
Guadalajara, Oaxaca City, Puebla City
2025-09-29
Recruiting
Pfizer
Phase 3
714
Guadalajara, Veracruz de Ignacio de LA Llave, Mexico City, Puebla City
2025-07-23
Active, closed
Eli Lilly and Company
Phase 3
465
Chihuahua City, Guadalajara, Mexico City, Monterrey, Puebla City, Tampico
2025-05-12
Active, closed
Eli Lilly and Company
Phase 3
905
Chihuahua City, Guadalajara, Hacienda de Las Palmas, Monterrey, Puebla City, Tampico
2025-04-25
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Saltillo, Mexico City, Pachuca, Guadalajara, Monterrey, Chihuahua City, Puebla City, Veracruz
2025-04-24
Active, closed
Celgene
Phase 3
960
Mexico City, Guadalajara, Monterrey, Chihuahua City, Puebla City
2025-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
530
Guadalajara, Puebla City
2025-02-25
Recruiting
Eli Lilly and Company
Phase 3
55
Ciudad Madero, Puebla City, Tampico, Tlalpan, Veracruz
2025-01-10
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Chihuahua City, Guadalajara, Mexico City, Monterrey, Puebla City, Querétaro, Tijuana
2024-12-12
Recruiting
Eli Lilly and Company
Phase 3
125
Culiacán, Guadalajara, Juriquilla, León, Mexico City, Puebla City
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Monterrey, San Nicolás de los Garza, San Juan del Río, Chihuahua City, Mexico City, Oaxaca City, Puebla City
2024-11-15
By invitation
University of California, San Francisco
Not applicable
872
Puebla City, Culiacán
2024-10-16
Active, closed
Novo Nordisk A/S
Phase 4
500
Monterrey, Ciudad Madero, Puebla City
2024-09-17
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
León, Zapopan, Cuauhtémoc, Monterrey, Puebla City
2024-09-12
Recruiting
Bayer
Phase 3
555
Mexico City, Monterrey, Naucalpan, Puebla City, San Pedro Garza García
2024-08-28
Active, closed
Celgene
Phase 3
850
Mexico City, Morelia, Monterrey, Oaxaca City, Puebla City
2024-06-19
Recruiting
Eli Lilly and Company
Phase 3
300
Aguascalientes, Guadalajara, Monterrey, Puebla City
2024-06-03
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Cuauhtémoc, Mexico City, Puebla City, Toluca
2024-02-20
Recruiting
Eli Lilly and Company
Phase 3
1,264
Guadalajara, Juriquilla, León, Mexico City, Monterrey, Oaxaca City, Puebla City, San Pedro Garza García
2023-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Guadalajara, Mexico City, Monterrey, San Luis Potosí City, Oaxaca City, Puebla City
2023-12-15
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Guadalajara, Mexico City, Puebla City, San Luis Potosí City, Monterrey, Oaxaca City, Sinaloa
2023-11-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Guadalajara, Monterrey, Oaxaca City, Puebla City
2023-11-12
Active, closed
Bristol-Myers Squibb
Phase 3
402
Oaxaca City, Huixquilucan, Mexico City, Puebla City
2023-10-24
Active, closed
Novo Nordisk A/S
Phase 3
212
Puebla City
2023-07-07
Recruiting
Myra Vision Inc.
Not applicable
60
Chihuahua City, Puebla City
2023-05-31
Active, closed
Stemline Therapeutics, Inc.
Phase 2
61
Monterrey, Mexico City, Puebla City
2023-05-19
Active, closed
Gilead Sciences
Phase 3
654
Cancún, Mexico City, México, Monterrey, Puebla City, San Pedro Garza García, Yucatán
2023-05-08
Active, closed
Bristol-Myers Squibb
Phase 3
516
Mexicali, León, Zapopan, Mexico City, Chihuahua City, Puebla City
2023-01-12
Active, closed
Gilead Sciences
Phase 3
1,021
México, Mitras Centro, Oaxaca City, Orizaba Centro, Puebla City, Veracruz
2022-10-12
Active, closed
Eli Lilly and Company
Phase 3
8,000
Chihuahua City, Ciudad Madero, Guadalajara, León, Mexico City, Monterrey, Oaxaca City, Puebla City
2022-10-04
Active, closed
Novo Nordisk A/S
Phase 3
412
Puebla City
2022-08-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Guadalajara, Mexico City, Monterrey, Querétaro City, Culiacán, Oaxaca City, Puebla City
2022-03-15
By invitation
Longitudinal Assessment of Pain-Related Patient-Reported Outcomes After Surgery
NCT05315596Pain, Postoperative, Adult, Pain Measurement, Functional Status
Jena University Hospital
Observational
1,000
El Bajo, León, Mexico City, Guadalajara, Puebla City, San Luis Potosí City
2022-02-01
Active, closed
Eli Lilly and Company
Phase 3
874
Torreón, Álvaro Obregón, Mexico City, Monterrey, San Pedro Garza García, Chihuahua City, Oaxaca City, Puebla City
2021-10-04
Active, closed
Novo Nordisk A/S
Phase 3
78
Puebla City
2021-03-04
Active, closed
AstraZeneca
Phase 3
1,371
Del. Cuauhtemoc, La Paz, Mexico City, Monterrey, Puebla City, Toluca
2021-01-28
Active, closed
Pfizer
Phase 3
257
León, Benito Juárez, Monterrey, Mexico City, Puebla City
2021-01-15
Active, closed
Medicago
Phase 2/3
30,918
Aguascalientes, Culiacán, Mexico City, Mérida, Puebla City, Veracruz, Zapopan
2020-11-19
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Durango, León, Monterrey, Naucalpan, Oaxaca City, Puebla City, Querétaro
2020-11-12
Active, closed
Sanofi
Observational
1,860
Cuernavaca, Monterrey, México, Puebla City, Tlalnepantla
2019-08-15
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-mexico/city/puebla-city

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,585 studies in total at the last sync on 12 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Puebla City.

How many clinical trials are recruiting in Puebla City?

23 of the 52 studies on this page are recruiting new participants as of the 12 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 27 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Puebla City), 52 studies
PhaseStudiesRecruitingShare
Phase 3412078.8%
Phase 2/3315.8%
Not applicable213.8%
Observational203.8%
Phase 2203.8%
Phase 1/2111.9%
Phase 4101.9%

Most active sponsors

Lead sponsors with the most studies (Puebla City)
Lead sponsorStudiesRecruiting
Eli Lilly and Company95
Bristol-Myers Squibb85
Novo Nordisk A/S73
Merck Sharp & Dohme LLC53
Pfizer32
Amgen20
Celgene20
Gilead Sciences20
AstraZeneca10
Bayer11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.